货号:GS40188
Domagrozumab (also known as PF-06252616) is an investigational fully human monoclonal antibody that was developed for the treatment of Duchenne muscular dystrophy (DMD). It was designed to target and inhibit myostatin (also known as growth differentiation factor 8, GDF-8), a negative regulator of skeletal muscle growth. By blocking myostatin, the drug aimed to promote muscle hypertrophy and increase muscle strength in patients with DMD. However, despite reaching Phase II clinical trials, its development was discontinued after it failed to demonstrate a statistically significant improvement in functional motor outcomes compared to placebo.
武汉迈思生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
迈思生物